Premium
High‐dose therapy/stem cell support: Comparison of mice and humans
Author(s) -
Teicher Beverly A.,
Northey David,
Yuan Jia,
Frei Emil
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960301)65:5<695::aid-ijc22>3.0.co;2-5
Subject(s) - thiotepa , melphalan , cyclophosphamide , medicine , carmustine , carboplatin , chemotherapy , pharmacology , cisplatin
A murine high‐dose therapy/stem cell support model is described using female BALB/c mice bearing the EMT‐6 mammary carcinoma. Peripheral blood cells were prepared in syngeneic donor animals mobilized by treatment with cyclophosphamide and rhG‐CSF. The most effective support regimen includes administration of fluid by gavage, rhG‐CSF twice per day for 12 days and peripheral blood cells administered i.v. on the day after cytotoxic therapy. Dose escalations of 2.2‐ to 13‐fold over the usual conventional dose were possible in mice treated with single doses of cyclophosphamide, carmustine, melphalan, thiotepa, carboplatin or total body radiation, which compare favorably with dose escalations achievable in humans. Depletion and recovery rates of white blood cells and granulocytes in the mice were similar to those seen in humans. Rapid weight loss is a major factor in limiting further dose escalation. Single high‐dose therapy with cyclophosphamide, melphalan, thiotepa and carboplatin, but not 5‐fluorouracil, produced longer tumor growth delays than standard regimens of the same drugs. For melphalan and thiotepa, there was a direct correlation between drug dose, tumor growth delay and tumor surviving fraction. With cyclophosphamide, the tumor growth delay with high‐dose therapy was greater than expected from the dose increase and the tumor surviving fraction data. © 1996 Wiley‐Liss, Inc.